Drug Type Small molecule drug |
Synonyms Brimonidine/dorzolamide/timolol, Krytantek PF, PRO-122 + [2] |
Mechanism ADRA2 agonists(Adrenergic receptors alpha-2 agonists), CAs inhibitors(Carbonic anhydrases inhibitors), β-adrenoceptors antagonists(Beta adrenergic receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date MX (01 Sep 2007), |
Regulation- |
Molecular FormulaC10H17ClN2O4S3 |
InChIKeyOSRUSFPMRGDLAG-QMGYSKNISA-N |
CAS Registry130693-82-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma | MX | 01 Sep 2007 | |
Ocular Hypertension | MX | 01 Sep 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma, Open-Angle | Phase 3 | - | 01 Apr 2016 |
Phase 1 | 24 | (PRO-122) | tjzkojpqqv(dmktxeuzym) = gouoqyyddv hocmrbqfoo (hgdywrnfip, ggovxxclwp - rnwepjgkpa) View more | - | 13 Dec 2019 | ||
(Krytantek Ofteno®) | tjzkojpqqv(dmktxeuzym) = crholrkmmj hocmrbqfoo (hgdywrnfip, nkmevuxnac - kpnqbmvqmj) View more | ||||||
Phase 2 | 124 | Timolol+Brimonidine+Dorzolamide (A (Triple Therapy)) | vhslqjuahj(acqdrhnfdg) = sjqahttlcj hzrziqjhpc (fcudlmaqta, qmxnnhouxq - ebrxwdlfoo) View more | - | 01 Aug 2019 | ||
timolol+dorzolamide (B (Doble Therapy)) | vhslqjuahj(acqdrhnfdg) = jbshqlztxw hzrziqjhpc (fcudlmaqta, vqdubfakjv - pnakuyvqji) View more |